Page 4«..3456..1020..»

What is Nanomedicine? The future of medicine.

Materials which have at least one dimension less than 100nm are classified as nanomaterials. These materials can be may shapes and sizes like spheres, rods, wires, cubes, plates, stars, cages, pyramids among some funny named shapes like nanohedgehogs, nanocandles and nanocakes! See the paperMorphology-Controlled Growth of ZnO Nanostructures Using Microwave Irradiation: from Basic to Complex Structuresfor some really inventive names for various shaped nanomaterials!

Aside scientists are pretty terrible at naming things, for example,the creative names given to optical telescopes the Extremely Large Telescope,Large Binocular Telescope,Overwhelmingly Large Telescope,Very Large Optical Telescope.

These nanoparticle shapes come in different sizes and different materials too. Broadly we can categorize nanomaterials into two groups organic or inorganic (but it is possible to have a hybrid inorganic-organic nanoparticle too). Organic nanoparticles arent nanoparticles from your local farmers market they are nanoparticles which contain carbon (and often hydrogen too which forms hydrocarbons) whereas most inorganic nanoparticles dont contain carbon atoms. Organic nanomaterials include carbon (except fullerenes) , polymeric and lipid-based nanocarriers. Inorganic nanoparticles include metallic/plasmonic, magnetic, upconversion, semiconductor and silica based nanoparticles.

The main groups of organic nanocarriers are liposomes, micelles, protein/peptide based and dendrimers. Protein/peptide based nanocarriers are amorphous (non-crystalline) materials generally conjugated to the therapeutic agent and is often further functionalised with other molecules. Micelles and liposomes are formed by amphiphilic (both hydrophilic and hydrophobic parts), micelles form monolayers whereas liposomes form bilayers. Lastly, dendrimer nanocarriers are tree-like structures which have a starting atom core (eg. nitrogen) and other elements are added through a series of chemical reactions resulting in a spherical branching structure. This final structure is not unlike blood hemoglobin and albumin macromolecules.

These vesicular nanocarriers can be used to trap both hydrophobic and hydrophilic drugs and even small nanoparticles inside the aqueous/lipid core. This provides protection for drugs and facilitates significant drug loading minimising toxicity and increasing blood circulation time (increasing possibility that the drug will reach the therapeutic target from avoiding opsonisation).

inorganic nanomaterials are stable, robust, resistant, highly functional. and are quite easily cleared from the body. Furthermore, inorganic material exhibit truly exciting mechanical, optical, physical and electrical phenomena at the nanoscale which can be tailored through changes in material, phase, shape, size and surface characteristics. Oftentimes, it is necessary to add a biocompatible surface to inorganic nanoparticles to avoid toxicity, especially for heavy metals.

Semiconductor Nanomaterials

Quantum dots are the most well-known semiconductor nanoemitter. These are typically very small in size ~5nm, which is smaller or equal to the exciton Bohr radius giving quantum confinement. Electrons are subatomic particles with a negative elementary electric charge, electron holes is an empty position in an atom or lattice that an electron could occupy. An exciton is a bound statewhere an electron and electron hole are electrostatically attracted to each other through Coulombic forces.Anexciton bohr radiusis the separation distance between the hole and electron. Due to 3 dimensional confinement effects, quantised energy levels are produced in the filled low energy valence band and in the empty conduction band of the quantum dots which is very unlike bulk semiconductors. The energy gap between the conduction and valance band varies with the size of the quantum dot which explains the tunable emissions (colour) when excited. Additionally, alloyed quantum dots can be further tuned because the bandgap is approximately equal to the weighted average of the composite semiconductor material. Quantum dots excited in the near-infrared are expected to be revolutionary in biomedical imaging. There has been concerns about the stability and toxicity, as many quantum dots lose luminescence intensity when exposed to light/air/oxygen/water and they are generally composed of heavy metal materials.

Upconversion Nanomaterials

Upconversion nanomaterials consist of two parts, first the host dielectric lattice (e.g., NaYF4) with one or more guest trivalent lanthanide (atomic numbers 5771) ions (e.g., Er3+, Yb3+). Upconversion is an anti-stokes process, two or more lower energy photons are absorbed (either simultaneously or stepwise) via long-lived real electronic states of the lanthanide dopant and a higher energy photon is emitted. The lanthanide element has a specific electronic configuration with energy levels which is usually independent of the host material type, the nanoparticle shape and its size.

Electrons are arranged in shells around an atoms nucleus, where the closest electrons to the nucleus have the lowest energy. Each shell can hold a certain number of electrons (principal quantum number) the first shell (1) can hold 2 electrons, the second (2) 8 and the third (3) 18. Within these shells are subshells (defined by theazimuthal quantum number) and are labelled s,p,d or f which can hold 2,6,10 or 14 electrons respectively.

In the case of upconversion, the 5s and 5p shells are full whereas the 4f-4f shells are not. But, because 5s and 5p are full they shield the 4f-4f shells which allows sharp line-like luminescence, i.e. the luminescencepeak is not broad. This luminescence is also resistant to photobleaching, high photostability and are nonblinking, which of course is beneficial over fluorescent molecules which experience high levels of degradation. Through careful design, upconversion nanomaterials can display a variety of emission and excitation wavelengths from UV to NIR.

These upconversion nanoparticles can be incorporated with photosensitizers to produce reactive oxygen species which generally require activation by UV light. This therapy procedure is calledPhotodynamic therapyand can be used for treating a wide range of medical conditions including malignant cancers and acne. Upconverison nanomaterials also have applications in multimodal imaging through the use of specific dopants high atomic number dopants for computed tomography (CT) imaging, radioisotopes for single-photon emission tomography (SPECT) imaging or positron emission tomography(PET) imaging.

MagneticNanomaterials

At the nanoscale, certain magnetic materials below a specific size exhibit a special form of magnetism called superparamagnetism. Superparamagnetic nanoparticles behave as single domain paramagnets when under an external magnetic field but once the field is removed there is no residual magnetisation. Typically, these materials areIron oxide nanoparticles. Additionally, these nanomaterials tend to be non-toxic and can be readily coated with molecules for further functionalization. These nanoparticles are commonly used as MRI contrast agentsinmagnetic resonance imaging (MRI).Furthermore, magnetic nanoparticles can be used in nanotherapy either through magnetic-field-directed drug delivery or through magnetic hyperthermia which involves localized heating of diseased tissues and therefore, cell death.

Silica Nanoparticles

Silica is a highly biocompatible biomaterial which is often used in nanomedicine.

Mesoporous silica nanoparticles are silica nanoparticles which have been template-patterned to have pores throughout the particle. This is done through the use of surfactants likeCetrimonium bromide(CTAB), which is extracted after synthesis leaving holes where the CTAB once was. In these pores, water insoluble materials can be added, such as drugs for chemotherapy, dyes for imaging or even small nanoparticles. These pore sizes can be controlled to encapsulate various sizes of biomolecules. Silica is often used to coat nanoparticles to achieve biocompatibility and to simplify further functionalisation.

PlasmonicNanomaterials

Now, saving the best for last plasmonic nanoparticles.

Plasmonic nanoparticles consist of noble metals like gold, silver, copper and aluminium. At the nanoscale, these materials can supportLocalized surface plasmons, which is a collective oscillation of the free surface electrons at the interface between the nanomaterial and the surrounding dielectric medium when resonance occurs between the natural resonant frequency of the surface electrons and the frequency of the incident light photons. The LSPR can be tuned with the material, size and shape of the nanoparticle.

Plasmonic nanoparticles can scatter and absorb light, for example, for smaller nanoparticles absorption tends to dominate (more light is absorbed which is generally converted to heat energy) and for larger nanoparticles scattering tends to dominate (which is exploited in bioimaging). For this reason, smaller nanoparticles are often used in photothermal therapy. InPhotothermal therapy, plasmonic nanoparticles accumulate in diseased tissues then are irradiated with resonant light, the nanoparticles absorb this light energy and convert it to heat energy, resulting in localised heating of the damaged tissue. This localised heating causes cell death, thus this therapy can be used for cancerous tumors. This heating can be visualised using thermographical measurements or using a dark field microspectroscope, plasmon scattering can be used in medical imaging. Please giveBiomedical applications of plasmon resonant metal nanoparticles, Liao et. al.a read for additional information.

Like Loading…

Read the rest here:
What is Nanomedicine? The future of medicine.

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Side Effects of Testosterone Replacement Therapy (TRT)

As with any medical intervention, the benefits of Low T therapy must be weighed against the potential risk of adverse reactions the side effects of testosterone replacement therapy can be a problem if not properly managed by a trained provider.

Just as Paracelsus says, whether testosterone replacement creates a poisonous or beneficial environment is largely dependent upon how the medication is delivered and dosed.

Poison is in everything, and no thing is without poison. The dosage makes it either a poison or a remedy. Paracelsus

Those who abuse testosterone and other androgens may experience significant and even life threatening side effects.

Somewhat similarly, if treatment of Low T is mismanaged or not carefully monitored, patients will experience a higher rate and increased severity of adverse reactions or possibly a complete lack of meaningful results.

For the most part, this discussion will deal with the side effects of testosterone replacement therapy (TRT) in general, but some attention will be given to particular differences in the variety of methods utilized for treatment of Low T.

You can also watch the video below to hear from one of our founding partners, Augie Galindo, PA-C about the side effects of testosterone replacement therapy.

This video is about the Side Effects of TRT. Every medical intervention has potential issues, and treating Low T is no different. Learn about our approach to monitor and maintain safe testosterone levels.

Some side effects seen with TRT are the direct result of the use of exogenous testosterone (testosterone not made naturally in the body).

Pharmaceutical grade testosterone is bio-identical, that is, it is constructed, recognized, and utilized in the same manner as the hormone produced by your body.

Many adverse effects occur only in the presence of higher testosterone levels, and still others are simply the consequences of the bodys normal metabolism of testosterone.

This metabolism, or breakdown of testosterone, occurs in the same manner for both exogenous and endogenous testosterone (naturally produced testosterone), but because of an increased abundance of testosterone this may lead to higher than normal levels of these metabolites.

Normal metabolism of testosterone results in its conversion into two primary metabolites, dihydrotestosterone (DHT) and estradiol (E2, a form of estrogen).

Elevated levels of DHT can cause benign growth of the prostate, increased oiliness of the skin and acne, as well as male pattern balding.

Abnormal increases in estradiol can lead to mood swings, breast tissue changes, and fluid retention that may cause swelling or increases in blood pressure. Furthermore, abnormal estradiol levels have been linked to lower testosterone levels, erectile dysfunction, and a decrease in free testosterone.

According to the 2010 update to Testosterone Therapy in Adult Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline, the conversion rate and subsequent ratio of testosterone to estradiol and DHT does not change when treating Low T via injection of testosterone cypionate.

These ratios may be negatively affected with other Low T treatments (gels, patches, pellets, etc.).

While prostate changes can occur with testosterone replacement, a study published in The Journal of Clinical Endocrinology & Metabolism in June of 2010, which looked closely at the adverse reactions reported in 51 other studies, found there to be no increased risk of the development of prostate cancer, prostate related urinary symptoms, or elevated PSA (prostate specific antigen).

Basically, prostate cancer is NOT one of the side effects of testosterone replacement therapy.

That aside, because PSA is essentially a tumor marker for prostate cancer, patients with a first-degree relative who has been diagnosed with prostate cancer and those with an elevated PSA level should proceed with caution and be monitored closely.

For men with a personal history of prostate cancer, treatment for Low T is considered contraindicated according to most sources.

It is important to note that testosterone replacement does not give you prostate cancer, but certainly elevated testosterone levels (even to the normal range) can cause an otherwise unnoticed prostate lesion to grow more aggressively.

Testosterone, in and of itself, is not a causative factor in the development of prostate cancer.

That myth has finally been debunked through countless studies over several years while more recent data now indicate that low serum testosterone levels are a potential predictor of high-risk prostate cancer.

The more interesting debate at this point is the potential consequence of increasing a mans testosterone level, even to a normal range, in the presence of an existing prostatic growth.

The findings of multiple studies over the years have ranged from testosterone appearing to be associated with promoting the transition of a common, low-grade lesion into one of a more aggressive nature, to testosterone actually contributing to cell death of the malignancy to no appreciable effect whatsoever.

Obviously the current data is inconclusive, however, it is becoming more and more apparent that as we ponder the safest recommendations, while peering through the lens of risk/benefit analysis, living with testosterone deficiency may indeed be the more risky endeavor.

The production of testosterone and sperm both are controlled by what is referred to as the Hypolthalamus-Pituitary-Gonadal Axis.

That is, the hypothalamus ( a portion of the forebrain responsible for the control of certain autonomic nervous system actions and pituitary gland activity) talks to the pituitary gland by mean of a chemical messenger (GnRH gonadotropin-releasing hormone).

The pituitary gland in turn will talk to the testicles (male gonads) also by means of different chemical messengers (LH luteinizing hormone and FSH follicular stimulating hormone).

Low T occurs when either this hormonal cycle fails to stimulate the testes to produce testosterone or more commonly when the testes themselves fail to respond to said stimulation.

When testosterone levels are normalized, either by natural means or through treatment of Low T, the brain reduces the stimulus to produce testosterone by secreting less GnRH.

Since this singular hormone controls both FSH and LH, the natural suppression of GnRH that occurs can reduce fertility.

Additionally, it is this same process that is responsible for the potential reduction in size and/or change in firmness of the testicles.

Other side effects of testosterone replacement therapy that are not part of normal functioning are increased red blood cell counts (erythrocytosis), potential decreases in good cholesterol or high-density lipoproteins (HDL), and increases in diastolic blood pressure (the lower of the two numbers reported in blood pressure readings).

The effects of high blood pressure are well known and the reasons for avoiding hypertension during TRT are no different from standard recommendations.

Increased number of red blood cells on the other hand, can lead to significant risk if not managed appropriately.

Think of red blood cells (RBCs) as the solid portion of the solution that is whole blood, and your hematocrit (HCT) the percentage of blood volume made up of RBCs.

If you add more solid to any solution without proportionately increasing the volume of the liquid it is suspended within, the result is a thicker solution.

Thickening of the blood then, is the end result of an increase in the number of RBCs.

Hematocrit values greater than 54.0% increase a patients risk factors for abnormal clotting, spleen enlargement, heart failure and other serious conditions.

If erythrocytosis does occur, it is typically rather easy to address. However if its assessment is overlooked, as is far too often the case, it can lead to potentially serious problems.

Certain side effects of testosterone replacement therapy are preparation specific. Gels, creams, and other topical agents can cause skin irritation and secondary exposure to women and children who come into contact with the medication via direct transfer.

Some untoward consequences of use of topicals is the wonderful odor (or fragrance, to steal Big Pharmas term) that is associated with it.

Failure rates are much, much higher for this type of medication owing to the inability of 30-40% of men to even absorb enough to improve their testosterone levels.

Virtually every medical treatment can cause adverse reactions. All things considered, the side effects of testosterone replacement therapy are quite manageable.

We know what to look for and how to intervene. With careful monitoring, it is entirely possible to treat and/or prevent significant problems these side effects may pose.

Ultimately it comes down to balance. Can we approach Low T treatment in such a way that allows for minimization of side effects while allowing for optimization of results? Absolutely!

What is necessary to achieve this is having providers who are open and honest about the benefits AND the risks associated with TRT. If you have questions, we would love the opportunity to talk with you and answer them.

Please Contact Us to schedule a no-obligation consultation in our clinic. If you are suffering from Low T and are ready to improve the quality of your life but are concerned about the side effects of testosterone replacement therapy (TRT), the dedicated providers at Testosterone Centers of Texas are ready to help you.

See original here:
Side Effects of Testosterone Replacement Therapy (TRT)

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Nanomedicine Conferences | NanoPharma Conferences 2018 …

Sessions/Tracks

ConferenceSeries Ltdis a renowned organization that organizes highly notableconferencesthroughout the globe. Currently we are bringing forth14thInternational Conference and Exhibition onNanomedicine andPharmaceutical Nanotechnology(NanoMed 2018)scheduled to be held duringApril 16-18, 2018atAmsterdam, Netherlands.The conferenceinvites all the participants across the globe to attend and share their insights and convey recent developments in the field of Pharmaceutical Nanotechnology and Clinical Trials.

The main theme of the conference is Emerging Importance of Nanotechnology to Drive the Pharma Industry.

ConferenceSeries Ltdorganizes aconference seriesof 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientificsocietiesand publishes 700+Open access Journalswhich contains over 50000 eminent personalities, reputed scientists as editorial board members.

14thInternational Conference and Exhibition onNanomedicineandPharmaceutical Nanotechnologyaims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nanotechnology and Nanomedicine. It also provides a premier interdisciplinary platform for researchers, practitioners and educators to present and discuss the most recent innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields ofNanotechnologyand Nanomedicine.

Medicinehas developed throughout time but has remained forever concerned with the maintenance of health and thus the science of prevention and alleviation, and ultimately curing, of disease. To continue its development in new directions, medicine is now looking to nanomedicine, an emerging scientific specialty born from nanotechnology, which has grown up in the fields ofengineering, physics,chemistryandbiotechnology, and is now moving into medicine, with huge potential for expansion and development over the next decade and beyond.

As our knowledge of the human body continues to improve, nanotechnology will be developed to monitor, repair and control human biological systems at the molecular level. This conference will offer unique opportunities for developing new therapeutic approaches to diagnose, prevent, treat and eradicate life-threatening diseases and conditions (such as cancer and diabetes), as well as resolving pain and improving medical techniques (such as bone repair and surgical techniques), through various novel nanotechnological approaches.

Nanomedicineis a uniquely addressing the important challenges and advances in medicalnanoscale-structured materialand devices,biotechnology devicesand molecular machine systems andnanorobotics. NanoMed 2018 is a valuable information source for all players in the field academic, industrial and clinical researchers, pharmaceutical and biotechnology companies,regulatory authoritiesand others across the scientific community.

Track 1:NanomedicineandBiomedical Applications:

Nanomedicineis simply the application of nanotechnologies in a healthcare setting and the majority of benefits that have already been seen involve the use ofnanoparticlesto improve the behaviour ofdrug substances. Today, nanomedicines are used globally to improve the treatments and lives of patients suffering from a range of disorders including ovarian andbreast cancer, kidney disease, fungal infections,elevated cholesterol, menopausal symptoms, multiple sclerosis, chronic pain,asthmaand emphysema. The nanomedicines that are currently available are overcoming some of the difficulties experienced by normal medical approaches in delivering the benefit from thedrug moleculesused. In some cases the drugs have very little solubility in water and the human body struggles to absorb enough to treat the condition. In other cases, the drug molecule is absorbed well but the body removes the drug before it has had long enough to provide a benefit. Drugs may lead to side-effects due to poor delivery at the actual site of disease. For example, drugs that are targeting cancers must avoid healthy tissues and organs or damage can be caused. Nanomedicines therefore can play an important role in ensuring enough of the drug enters the body, that drug that does enter stays in the body for long periods and is targeted specifically to the areas that need treatment.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain; 10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany; 23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 2:Design of Nanodrugs

To date, variousnanodrug systemshave been developed for different routes of administration, which include dendrimers,nanocrystals, emulsions, liposomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles. Nanodrug systems have been employed to improve the efficacy, safety, physicochemical properties, and pharmacokinetic/pharmacodynamic profile of pharmaceutical substances. In particular, functionalized nanodrug systems can offer enhancedbioavailabilityof orally taken drugs, prolonged half-life of injected drugs (by reducing immunogenicity), andtargeted delivery to specific tissues. Thus,nanodrug systemsmight lower the frequency of administration while providing maximized pharmacological effects and minimized systemic side effects, possibly leading to better therapeutic compliance and clinical outcomes. In spite of these attractive pharmacokinetic advantages, recent attention has been drawn to the toxic potential of nanodrugs since they often exhibit in vitro and in vivo cytotoxicity, oxidative stress, inflammation, and genotoxicity

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain; 10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany; 23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 3:Design & Characterization of Nanosystems

Micro andNanosystemspublishes significant original work, topical reviews and guest edited issues ranging from technologies and systems to product innovation and new manufacturing processes with features at the micro and nanoscale. Applications for micro and nanosystems in areas such as health, environment, food, security and consumer goods are covered. The topics to be addressed include Lab-on-a-chip,microfluidics, nano-biotechnology, micro andnanomanufacturing, printed electronics and MEMS.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain; 10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany; 23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 4:NanomedicineandNanotechnology

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use ofnanoscale materials, such as biocompatible nanoparticles andnanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism.Nanotechnologyhas many definitions but in general it is the use and application of materials with sizes in the nanometre range. Just as a millimetre is one-thousandth of a metre, a nanometre is one-millionth of a millimetre. In more understandable terms, a human hair is approximately 80,000 nanometres in diameter and the growing science and industry of nanotechnology utilises materials below 1000 nanometres. Benefits of working at this very small scale have been seen for many years over such diverse areas as electronics and energy storage to sunscreens and food packaging.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain; 10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany; 23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 5:Pharmaceutical Nanotechnology

Pharmaceutical Nanotechnologydeals with emerging new technologies for developing customized solutions fordrug delivery systems. The drug delivery system positively impacts the rate of absorption, distribution, metabolism, and excretion of the drug or other related chemical substances in the body. In addition to this the drug delivery system also allows the drug to bind to its target receptor and influence that receptors signaling and activity. Pharmaceutical nanotechnology embraces applications of nanoscience to pharmacy asnanomaterials, and as devices likedrug delivery, diagnostic, imaging and biosensor.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain; 10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany; 23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 6:Synthesis of NanoparticlesforDrug Delivery

Synthesizingnanoparticlesfor pharmaceutical purposes such as drug preparation can be done in two methods. Bottom up process such as pyrolysis, inert gas condensation, solvothermal reaction, sol-gel fabrication and structured media in which hydrophobic compound such asliposomesare used as bases to mount the drug. Top down process such as attrition / milling in which the drug is chiseled down to form a nanoparticle.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain; 10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany; 23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 7:Regenerative MedicineandTissue Engineering

Tissue engineeringis a branch of regenerative medicine, itself a branch ofbiomedical engineering. Tissue engineering andregenerative medicineare concerned with the replacement or regeneration of cells, tissues (the focus of tissue engineers) or organs to restore normal biological function.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 8:Drug Delivery Research

Drug deliveryis an essential part ofpharmaceutical sciencesthat should be taken into account early in thedrug discoveryand development process. A drug that cannot be delivered to its site of action is essentially useless. Drug delivery is affected by the physico-chemical properties of the drug and formulation and the interplay of these factors with the transport, binding, and metabolism of the drug in the body. New tools are needed to accurately predict delivery properties of the compounds early during drug discovery, so that the best compounds can be identified for clinical studies. Another class of tools includes the delivery methods that facilitate delivery of hard-to-deliver compounds to the appropriate target sites. Delivery of gene-based drugs (DNA, oligonucleotides, siRNA) and proteins is a major challenge in pharmaceutical science. Nanotechnology can be used to improve drug delivery in these difficult cases. The development and use of nanoparticles in theformulationof these types of drugs is a major focus at CDR, and we welcome productive industrial partnerships to develop these tools for translational use.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 9:Novel Drug Delivery Systems

Novel Drug delivery systemis the advancedrug delivery systemwhich improvedrug potency,control drug releaseto give a sustained therapeutic effect, provide greater safety, finally it is to target a drug specifically to a desired tissue.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 10:Smart Drug Delivery Technology

With the unprecedented progresses ofbiomedical nanotechnologyduring the past few decades, conventionaldrug delivery systems(DDSs) have been involved into smart DDSs with stimuli-responsive characteristics. Benefiting from the response to specific internal or external triggers, those well-defined nanoplatforms can increase the drug targeting efficacy, in the meantime; reduce side effects/toxicities of payloads, which are key factors for improving patient compliance. In academic field, variety of smart DDSs have been abundantly demonstrated for various intriguing systems, such as stimuli-responsivepolymeric nanoparticles, liposomes, metals/metal oxides, and exosomes.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 11:Nano Pharmaceuticals

Nanopharmaceuticalsoffer the ability to detect diseases at much earlier stages and the diagnostic applications could build upon conventional procedures using nanoparticles. Nanopharmaceuticals represent an emerging field where the sizes of thedrug particleor a therapeutic delivery system work at thenanoscale. In the pharmaceutical industry, a long standing issue is the difficulty of delivering the appropriate dose of a particular active agent to specific disease site. Nanopharmaceuticals have enormous potential in addressing this failure of traditional therapeutics which offers site-specific targeting of active agents. Such precision targeting via nanopharmaceuticals reduces toxic systemic side effects, resulting in better patient compliance. In todays world economy, apharmaceutical industryfaces enormous pressure to deliver high-quality products to patients while maintaining profitability. Thereforepharmaceutical companiesare applying nanotechnology to enhance or supplement drug target discovery anddrug delivery. Nanopharmaceutical reduces the cost of drug discovery, design & development and enhances the drug delivery process. This results in the improvedResearch & Developmentsuccess rate which enables faster introduction of new, cost-effective products to the marketplace.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

Related Societies:

Societies in USA:American Academy of Nanomedicine,Nano Canadian Society,American Nano Society,American Society for Nanomedicine,Society for Personalized Nano MedicineInternational Association of NanotechnologyandGraphene Stakeholders Association

Societies in Europe:Nanotechnology Industries Association,Royal Microscopical Society,Royal Society – Nanotechnology and Nanoscience,British Society for Nanomedicine,European Society for Nanomedicine,French Society for Nanomedicine,European NanoBusiness Association,European Society for Precision Engineering and Nanotechnology,Czech Nanotechnology Industries AssociationandErwin Schrdinger Society for Nanosciences

Societies in Asia:National Center for Nanoscience and Technology,Indian Society for Nanomedicine,Nano Technology Research AssociationandIndian Society of Nanomedicine.

Track 12:Nanobiotechnology

Nanobiotechnology,bionanotechnology, and nanobiology are terms that refer to the intersection of nanotechnology andbiology. This discipline helps to indicate the merger of biological research with various fields of nanotechnology. Concepts that are enhanced throughnanobiologyinclude:nanodevices(such asbiological machines), nanoparticles, and nanoscale phenomena that occurs within the discipline of nanotechnology. This technical approach to biology allows scientists to imagine and create systems that can be used forbiological research. Biologically inspired nanotechnology uses biological systems as the inspirations for technologies not yet created.

Related Conferences:NanoPharma Conferences|Nanomedicine Symposium|Nanomedicine Conferences|Nanomedicine Meetings|Nanomedicine Congress|Nanopharma Meetings

12thPharmaceutical Sciences andPharma Industry ConferenceFebruary 26- 27 2018,London, UK; 7thEuropeanBiosimilars Conference, April 26-27, 2018, Rome,Italy; 13thEuropean Pharma ConferencesMay 07-09, 2018 at Frankfurt,Germany; 4thMarine Drugs andNatural Products Conferences, June 11-13, 2018 atRome, Italy; 9thGlobal ExpertsMeeting on Neuropharmacology, June 18-19, 2018 atParis, France; 4thConference onAntibiotics Conference; June 14-15, 2018,Barcelona, Spain;Nanomedicine Conferences 2018 USA;10thPharmacology Conferencesduring July 30-August 01, 2018 at Barcelona,Spain; 8thEnvironmental Chemistry Conference, September 20-22, 2018 Berlin,Germany;Nanomedicine Conferences 2018 Asia;23rdConference on Nanomaterialsand Nanotechnology, March 15-16, 2018 at London,UK; 3rdConference On Nanomedicine, Drug Delivery, and Tissue Engineering, April 10 – 12, 2018 at Budapest,Hungary;World Congress on Nanotechnologyand Material Science, April 16-18, 2018 at Valencia,Spain; Conference onEmerging Trends in Materials Science and Nanotechnology, April 26-27, 2018 at Rome,Italy; 24thWorld Nano ConferenceMay 07-08, 2018 at Rome,Italy;Conference on Nanoscience& technology, May 21-22, 2018 at New York,USA; 20thConference on Nanotechnologyand Nanomedicine, July 9 – 10, 2018 at Prague, Czechia;Nanomedicine Conferences 2018 Asia;Conference on Nanotech & Nanobiotechnology, July 12-13, 2018 at Paris,France; 20thConference on Nanoscience, Nanotechnology and Advanced Materials, August 13 – 14, 2018 at Venice,Italy.

See the original post here:
Nanomedicine Conferences | NanoPharma Conferences 2018 …

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Nanomedicine – Overview – NIH Common Fund

Background

Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve. A nanometer is one-billionth of a meter, too small to be seen with a conventional lab microscope. It is at this size scale about 100 nanometers or less that biological molecules and structures operate in living cells.

The NIH vision for Nanomedicine is built upon the strengths of NIH funded researchers in probing and understanding the biological, biochemical and biophysical mechanisms of living tissues. Since the cellular machinery operates at the nanoscale, the primary goal of the program – characterizing the molecular components inside cells at a level of precision that leads to re-engineering intracellular complexes – is a monumental challenge.

The teams selected to carry out this initiative consist of researchers with deep knowledge of biology and physiology, physics, chemistry, math and computation, engineering, and clinical medicine. The choice and design of experimental approaches are directed by the need to solve clinical problems (e.g., treatment of sickle cell disease, blindness, cancer, and Huntingtons disease). These are very challenging problems, and great breakthroughs are needed to achieve the goals within the projected 10 year timeframe. The initiative was selected for the NIH Roadmap (now Common Fund) precisely because of the challenging, high risk goals, and the NIH team is working closely with the funded investigators to use the funds and the intellectual resources of the network of investigators to meet those challenges.

10 Year Program Design High Risk, High Reward

The Centers were funded with the expectation that the first half of the initiative would be more heavily focused on basic science with increased emphasis on application of this knowledge in the second five years. This was a novel, experimental approach to translational medicine that began by funding basic scientists interested in gaining a deep understanding of an intracellular nanoscale system and necessitated collaboration with clinicians from the outset in order to properly position work at the centers so that during the second half of the initiative, studies would be applied directly to medical applications. The program began with eight Nanomedicine Development Centers (NDCs), and four centers remain in the second half of the program.

Clinical Consulting Boards (CCBs)

The program has established Clinical Consulting Boards (CCBs) for each of the continuing centers. These boards consist of at least three disease-specific clinician-scientists who are experts in the target disease(s). The intent is for CCBs to provide advice and insight into the needs and barriers regarding resource and personnel allocations as well as scientific advice as needed to help the centers reach their translational goals. Each CCB reports directly to the NIH project team.

Translational Path

In 2011, the PIs of the NDCs worked with their CCBs to precisely define their translational goals and the translational research path needed to reach those goals by the end of the initiative in 2015. To facilitate this, the NIH project team asked them to develop critical decision points along their path. These critical decision points differ from distinct milestones because they may be adjusted based on successes, challenges, barriers, and progress. Similarly, the timing of these decision points may be revised as the centers progress. Research progress and critical decision points are revisited several times a year by the CCB and the NIH team, and when a decision point is reached, next steps are re-examined for relevance, feasibility and timing.

Transition plan

Throughout the program, various projects have been spun off of work at all the centers and most have received funding from other sources. This was by design as work at each center has been shifting from basic science to translational studies. Centers will not be supported by the common fund after 10 years. It is expected that work at the centers will be more appropriately funded by other sources. Pre-clinical targets will likely be developed, and the work at each center will be focused on a specific disease so the work will need to transition out of the experimental space of the common fund.

Support for the NIH Nanomedicine Initiative is provided by the NIH Common Fund, and a team of staff members from across the NIH oversees the program. You may direct questions or comments on the NIH Nanomedicine Initiative to Dr. Richard S. Fisher, Nanomedicine Project Team Leader (nano@nih.gov).

Excerpt from:
Nanomedicine – Overview – NIH Common Fund

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Nanomedicine – Overview

The program began in 2005 with a national network ofeight Nanomedicine Development Centers. Now, in the second half of this 10-year program, the four centers best positioned to effectively apply their findings to translational studies were selected to continue receiving support.

Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve. A nanometer is one-billionth of a meter, too small to be seen with a conventional lab microscope. It is at this size scale about 100 nanometers or less that biological molecules and structures operate in living cells.

The NIH vision for Nanomedicine is built upon the strengths of NIH funded researchers in probing and understanding the biological, biochemical and biophysical mechanisms of living tissues. Since the cellular machinery operates at the nanoscale, the primary goal of the program – characterizing the molecular components inside cells at a level of precision that leads to re-engineering intracellular complexes – is a monumental challenge.

The teams selected to carry out this initiative consist of researchers with deep knowledge of biology and physiology, physics, chemistry, math and computation, engineering, and clinical medicine. The choice and design of experimental approaches are directed by the need to solve clinical problems (e.g., treatment of sickle cell disease, blindness, cancer, and Huntingtons disease). These are very challenging problems, and great breakthroughs are needed to achieve the goals within the projected 10 year timeframe. The initiative was selected for the NIH Roadmap (now Common Fund) precisely because of the challenging, high risk goals, and the NIH team is working closely with the funded investigators to use the funds and the intellectual resources of the network of investigators to meet those challenges.

10 Year Program Design High Risk, High Reward

The Centers were funded with the expectation that the first half of the initiative would be more heavily focused on basic science with increased emphasis on application of this knowledge in the second five years. This was a novel, experimental approach to translational medicine that began by funding basic scientists interested in gaining a deep understanding of an intracellular nanoscale system and necessitated collaboration with clinicians from the outset in order to properly position work at the centers so that during the second half of the initiative, studies would be applied directly to medical applications. The program began witheight Nanomedicine Development Centers(NDCs), and four centers remain in the second half of the program.

Clinical Consulting Boards (CCBs)

The program has establishedClinical Consulting Boards (CCBs)for each of the continuing centers. These boards consist of at least three disease-specific clinician-scientists who are experts in the target disease(s). The intent is for CCBs to provide advice and insight into the needs and barriers regarding resource and personnel allocations as well as scientific advice as needed to help the centers reach their translational goals. Each CCB reports directly to the NIH project team.

Translational Path

In 2011, the PIs of the NDCs worked with their CCBs to precisely define their translational goals and the translational research path needed to reach those goals by the end of the initiative in 2015. To facilitate this, the NIH project team asked them to developcritical decision pointsalong their path. These critical decision points differ from distinct milestones because they may be adjusted based on successes, challenges, barriers, and progress. Similarly, the timing of these decision points may be revised as the centers progress. Research progress and critical decision points are revisited several times a year by the CCB and the NIH team, and when a decision point is reached, next steps are re-examined for relevance, feasibility and timing.

Transition plan

Throughout the program, various projects have been spun off of work at all the centers and most have received funding from other sources. This was by design as work at each center has been shifting from basic science to translational studies. Centers will not be supported by the common fund after 10 years. It is expected that work at the centers will be more appropriately funded by other sources. Pre-clinical targets will likely be developed, and the work at each center will be focused on a specific disease so the work will need to transition out of the experimental space of the common fund.

Support for the NIH Nanomedicine Initiative is provided by the NIH Common Fund, and a team of staff members from across the NIH oversees the program. You may direct questions or comments on the NIH Nanomedicine Initiative to Dr. Richard S. Fisher, Nanomedicine Project Team Leader (nano@nih.gov).

More here:
Nanomedicine – Overview

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Low Testosterone (Low T) Treatments – onhealth.com

What Is Testosterone?

Testosterone is a hormone that is necessary for proper muscular development and masculinity. Testosterone is made in the testes (testicles). Women also have testosterone, but in much smaller amounts than in men. If testosterone levels are below normal, a doctor may prescribe one of several types of treatments. However, there is debate about who needs to be treated.

Testosterone levels decrease as men age. Sometimes this lower level of testosterone is termed “andropause” or “male menopause.” Symptoms of male menopause may not be caused by low testosterone, but additional research is needed. Many men do not show any symptoms of decreasing levels of testosterone.

Although osteoporosis (brittle bone disease) is usually thought of as occurring mainly in women, the disease in men is commonly caused by low testosterone. Low testosterone levels can cause bones to thin, weaken, and become more likely to fracture.

Low testosterone doesn’t always interfere with sex, but it is possible. Some men with low testosterone may experience a drop in libido while others lose interest in sex completely. Low testosterone levels can make sex more difficult because it may be tougher to get or keep an erection. Low testosterone might not be the sole cause of low libido; stress, sleep deprivation, depression, and chronic medical illnesses can also alter a man’s sex drive.

Some of the changes that may occur with low testosterone are nonspecific symptoms such as easy irritability, mood changes, poor concentration, and feeling fatigued or having less energy. However, these symptoms may be caused by a condition other than low testosterone.

One of the many functions of testosterone is to help produce sperm. When testosterone levels are low, the “sperm count” can also be low. If the sperm count is very low, the man may not be able to father a child.

Although increased age is the most common cause of decreased testosterone levels in men, there can be other causes. Other common causes include:

You might need to be tested for low testosterone if you have erectile dysfunction (ED), a very low sex drive, low sperm count, loss of body hair, decrease of muscle mass, and osteoporosis. Conditions other than low testosterone could be the underlying cause of one’s symptoms. A doctor will want to rule out other conditions before diagnosing and treating low testosterone.

Tests for testosterone levels are done by sampling the blood early in the morning when levels of testosterone are highest. Your doctor may want to run a second test a few days later to check for consistency in testosterone levels measured. Normal testosterone levels range from about 300 to 1000 nanograms per deciliter (ng/dL), although some labs consider 200 ng/dL the cutoff for low testosterone. Your doctor will help interpret the tests for you.

If you are diagnosed with low testosterone, your primary care doctor may suggest you see a specialist such as an urologist or an endocrinologist. Not everyone with low testosterone will need or qualify for treatment. These specialists will help guide your treatment and design an approach to your low testosterone problem that is best for you.

Low testosterone treatment is designed to boost testosterone levels. Studies suggest this increase in testosterone can strengthen muscles, protect bones, and improve sex drive. Testosterone replacement therapy is only recommended for men who have blood levels that show low testosterone. Such treatments can have different effects from one man to another so it is difficult to predict the treatment outcomes for any one individual.

Testosterone injections are the least expensive form of testosterone treatment, but they can be painful. The shots are given about every 7 to 22 days and the body slowly absorbs the testosterone into the bloodstream. Injections can be given into the muscles or implanted as pellets. Testosterone levels can increase and then fall between shots.

Gel or patch treatments for low testosterone are placed directly on the skin. The hormone seeps out of the patch or gel and goes through the skin, and is slowly absorbed into the blood. Gels and patches are applied every day, and as a result, the level of testosterone remains fairly steady. A drawback to these treatments is they sometimes can cause itching, skin irritation, and blisters. In addition, women or children should not come in contact with skin that has been treated with a gel for 2 hours to avoid absorbing any testosterone.

Buccal patches are placed on the gums above the incisors (teeth) about every 12 hours and slowly release testosterone. They are not effective if swallowed. Buccal patches may cause a bitter taste, irritation to mouth tissues and gums, and may cause headaches. Fortunately, these side effects lessen over time. The patient can eat, drink, and kiss others while using buccal patches because they are not directly exposed to testosterone.

Although testosterone therapy has been tried in many individuals, the risks and benefits of this treatment over many years is still not known because such studies are still underway. Testosterone should not be given to men with untreated prostate cancer, untreated sleep apnea, or untreated breast cancer. In some men, testosterone therapy may need to be stopped if the risks outweigh the benefits.

IMAGES PROVIDED BY:

REFERENCES:

2005-2017 WebMD, LLC. All rights reserved.

Read the original here:
Low Testosterone (Low T) Treatments – onhealth.com

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Transhumanism: The Anti-Human Singularity Agenda

x

Uri Dowbenko, Conscious ReporterWaking Times

At a TED-like techno-geek symposium in the 2014 film Transcendence, Artificial Intelligence guru Dr. Will Caster (Johnny Depp) is asked by an audience member, So you want to create your own god? And he answers, Isnt that what man has always done?

This smarmy remark is indicative of the hubris and arrogance of scientism, the belief that science can solve all the problems on this planet, while scientists can have fun playing god at the same time.

It could also have been the answer of Real-Life Techno-Wizard Ray Kurzweil, Googles Director of Engineering, whose book The Singularity is Near: When Humans Transcend Biology (2005), is ever so popular with scientific materialists who neither have the capacity nor the desire for spiritual evolution, but have a fervent belief that the shotgun marriage of man and machine is not only normal but something to be ardently pursued.

Simply put Kurzweils sociopathic quest for digital immortality is based on his fear of death. He claims to take 150 pills a day in order to still be half-alive when voodoo science will have succeeded in uploading his sorry-state mind into a digital facsimile of his former self into cyber-space.

No soul? No problem

Since materialist scientists dont understand multi-dimensional or spiritual realities, they are unconcerned about the details which they cant even fathom.

And what exactly is the Singularity supposed to be? Its a future mythological moment when machine (artificial) intelligence becomes more intelligent than human intelligence.Kurzweils thesis and fervent hope is that it will occur by 2045. He writes that it is a future period during which the pace of technological advance will be so rapid, its impact so deep, that human life will be irreversibly transformed The Singularity will represent the culmination of the merger of our biological thinking and existence with our technology, resulting in a world that is still human but transcends our biological roots. There will be no distinction, post-Singularity, between human and machine or between physical and virtual.

Does that sound like science or a religious Belief System (B***)?

Despite a lackluster script, Transcendence is worth seeing because it is another example of Illuminati predictive programming in popular sci-fi movies. After all todays Hollywood Illuminati make the best movies, which are also the best propaganda for preparing humanity to accept One World Global Techno-Feudalism.

Eliminating humanity altogether also appears to be one of their goals as they seem to believe that the Humanity Experiment for all intents and purposes is finished. And, if they realize their twisted vision, humanity will in actuality become completely superfluous on Terra.

A Charlie Sheen movie called The Arrival comes to mind, in which an alien race is terra-forming Planet Earth to fit their requirements which are far different from that of humanity. They need a darker and more humid climate like the one in which dinosaurs roamed the earth. Obviously geo-engineering spraying chemtrails around the world and other forms of weather manipulation using HAARP technology, etc. are used in this so-called climate change scenario. Of course humans are always blamed for using the petro-chemical technology with which they have enslaved humanity in this age.

Now the plan to get rid of those pesky humans appears to have accelerated as the movie Transcendence introduces the concept of transhumanism to the hand-held electronics-addled masses.

Transhumanism itself was coined by Aldous Huxleys brother, biologist Julian Huxley, in 1957, when he wrote The human species can, if it wishes, transcend itself not just sporadically, an individual here in one way, an individual there in another way, but in its entirety, as humanity. We need a name for this new belief. Perhaps transhumanism will serve: man remaining man, but transcending himself, by realizing new possibilities of and for his human nature. (Religion Without Revelation, p.27)

Even Illuminati Gofer Julian Huxley called it a belief, since he knew that immortality was the Illuminati goal in life. After all, transhumanism has been aptly named the Rapture of the Geeks.

Reviewers of the movie have failed to put the film in context with real-life science, wherein techno-mischief makers like Google have plenty of cash to make their dream of transhumanism a reality. It should be noted that Google has been buying up companies like Boston Robotics, which makes killer robots, Deep Mind Technologies, an artificial intelligence company, NEST Labs, which plans to monitor your life through interactive appliances called the Network of Things and Project Calico, a genetic engineering project to defeat death itself, as their hype goes.

Scooping up human DNA into a gigantic database also seems to be one of Googles goals. A Google-wannabe subsidiary called 23andMe, founded by the wife of a Google founder, has as its stated goal creating the worlds largest secure, private database of genotypic and phenotypic information that can be used for comparison analysis and research. Of course Google has included a disclaimer in the Terms of Use which states Genetic information you share with others could be used against your interests. And this wonderful Monopoly Capitalism zinger as well By providing any sample, you acquire no rights in any research or commercial products that may be developed by 23andMe or its collaborating partners.

According to a New York Magazine article called The Google of Spit, by the end of 2013, 23andMe had extracted and analyzed DNA from 650,000 people, making it one of the biggest genetic banks in the world. Like any other Google scam, you sign away your rights but this time its your genetic program its your DNA.

Will Google be able harvest your soul in the future?

As New York Magazine put it In September, just a month after Wojcicki [wife of Google founder Sergey Brin] and Brin announced their separation, Google announced the launch of a new venture called Calico. Though its exact mission and purpose remain unclear, the general idea is for Calico to solve death, as Time magazine put it, in an uncanny echo of Wojcickis [founder of 23andMe] promise to solve health.

Solve health? Solve death? Theres no so-called problem these Arrogant Techno-Creeps cant handle

And then theres DARPA (Defense Advanced Research Project Agency), the Pentagons black-magic voodoo-science department that wants to create among other things replicant super-soldiers as portrayed by Rutger Hauer in the movie Blade Runner or Kurt Russel in Soldier for the Illuminatis future wars which will then inevitably morph into autonomous killing robots as seen in the RoboCop and Terminator films.

Coincidentally in a book by Wikileaks founder Julian Assange called When Wikileaks Met Google (2014), we discover Surprise! Google was actually partially funded by the sinister DARPA, the Pentagon Devils Workshop. Heres a footnote from the book

Acknowledgments, in The Anatomy of a Large-Scale Hypertextual Web Search Engine, Sergey Brin, Lawrence Page (Computer Science Department, Stanford University, 1998): The research described here was conducted as part of the Stanford Integrated Digital Library Project, supported by the National Science Foundation under Cooperative Agreement IRI-9411306. Funding for this cooperative agreement is also provided by DARPA and NASA, and by Interval Research, and the industrial partners of the Stanford Digital Libraries Project, archive.today/tb5VL.

In an excellent documentary called Google and the World Brain, WIRED magazine writer Kevin Kelly asked Google founder Larry Page back in the olden days, Why would anyone want a new search engine when we have Alta Vista?

And Page replied, Its not to make a search engine. Its to make an A.I.

The documentary also quotes Ray Kurzweil before he was hired as Googles Director of Engineering saying We talked to Google about their quest to digitize all knowledge and then create an A.I.

Googles corporate goal appears to be not only to steal all words, books, images, video, music, etc. through its search engine and other subsidiaries like Google Books, You Tube, etc. but then to monetize this wholesale theft on a worldwide scale.

This global library of information can then be transformed into a super-cyber-godlike Artificial Intelligence, which literally may become tantamount to SkyNet of Terminator movie fame.

In Transcendence, the Johnny Depp character turns into an uploaded cyberspace version of his former human self. Disguised as a cautionary tale, the movie is presented as a fait accompli, since the mad scientists of Google and DARPA are undoubtedly working day and night to initiate the so-called Singularity a confluence of the so-called GRIN technologies Genetic, Robotic, Information processing, and Neuro-technological processing.

By merging Artificial Intelligence, Nanotechnology, and Synthetic Biology, augmented by geo-engineering and Genetically Modified (GM or weaponized) food crops, these voodoo priests and rabbis of transhumanism are attempting to create a consensual virtual reality in which humans have become irrelevant because they are not augmented like those who have A.I. enhanced techno-gadgets, granting them super-powers, super-knowledge or super-intelligence. These synthetic or artificial siddhis (spiritual powers), they believe, will make them much more than mere mortal humans.

Like SkyNet, the all-powerful Artificial Intelligence in Jim Camerons Terminator movies, which sees humans as the enemy because it has no use for humans, Johnny Depps uploaded super-mind in Transcendence becomes a kind of cyber-god which craves more energy and power, not only to survive, but to expand itself and control everything on Earth.

Or as the Depp character tells his TED fanboys at the symposium Imagine a machine with the full range of human emotion. Its analytical power will be greater than the collective intelligence of every person in the history of the world. Some scientists refer to this as the singularity. I call it transcendence.

The problem with Singularity is that these materialistic scientists dont even understand what consciousness is, yet believe that uploading a human brain into a computer environment is somehow akin to transcending humanity even if its just a synthetic copy of a persons memories, etc.

They call it H+ which implies a superior human (Homo Superior) as opposed to Homo Sapiens.

The reality may be a little different, since the Illuminati plan for humanity is genetically engineering Homo Sapiens into Homo Deus.

Or is it Homo Insanus?

After all. No soul? No problem

Even Nobel Prize winner Stephen Hawking has written about his foreboding regarding transhumanism and the movie Transcendence in a UK Independent op-ed piece.

Of course Hawking doesnt say that Google is equivalent to Skynet, but he appears to be concerned about the dangers of an A.I. arms race, since mega-corporations like the sinister Google and Apple, as well as the sinister DARPA, are using their formidable resources of money and high-tech labor to try to produce an A.I. as soon as possible. Hawkins writes its tempting to dismiss the notion of highly intelligent machines as mere science fiction. But this would be a mistake, and potentially our worst mistake in history.

And why does Hawking sound a warning about the dangers of A.I.? Because he knows that as a cripp(term used by the handicapped as short for cripple), he would have been terminated as a useless eater.

The movies premise that Artificial Super Intelligence, a/k/a The Uploaded Johnny Depp 2.0 is a threat to humanity is of serious concern to Hawking and that dismissing the film as just science fiction could be the worst mistake in history, implies that film director Jim Camerons scenario in Terminator 2, wherein the A.I. based SkyNet overpowers the humans is not simply an idle threat but a very real problem since morality-and-ethics-free robots who are soul-less beings are an existential threat to humanity itself.

Hawking argues that developments in so-called digital personal assistants like Apples Siri and Google Now show a current I.T. Information Technology arms race which pales against what the coming decades will bring.

Success in creating A.I. would be the biggest event in human history, writes Hawking Unfortunately, it might also be the last, unless we learn how to avoid the risks.

Another opponent of the Singularity agenda is Bill Joy, who wrote an article for WIRED Magazine called Why the future doesnt need us: Our most powerful 21st-century technologies robotics, genetic engineering, and nanotech are threatening to make humans an endangered species.

Joy quotes from Kurzweils book The Age of Spiritual Machines, wherein he finds himself most troubled by this passage

The New Luddite Challenge

On the other hand it is possible that human control over the machines may be retained. In that case the average man may have control over certain private machines of his own, such as his car or his personal computer, but control over large systems of machines will be in the hands of a tiny elite just as it is today, but with two differences.

Due to improved techniques the elite will have greater control over the masses; and because human work will no longer be necessary the masses will be superfluous, a useless burden on the system. If the elite is ruthless they may simply decide to exterminate the mass of humanity. If they are humane they may use propaganda or other psychological or biological techniques to reduce the birth rate until the mass of humanity becomes extinct, leaving the world to the elite.

In the book, you dont discover until you turn the page that the author of this passage is Theodore Kaczynski the Unabomber.

By the way Luddite is a derogatory term for anyone who is opposed to technological so-called advances for any reason whatsoever.

And of course what the alleged Unabomber Ted Kaczynski, who was a mind control experimentation victim at Harvard, meant in his screed was that propaganda is actually so-called news, psychological techniques is the Malthusian belief system that there are too many humans on earth, and biological techniques means genetically modified foods and vaccines to cull the herd. In other words, he is predicting the Illuminati vision for the future a future bereft of what Illuminati Kingpin Henry Kissinger called useless eaters.

Then Bill Joy, cofounder and Chief Scientist of Sun Microsystems, gets positively metaphysical, writing I think it is no exaggeration to say we are on the cusp of the further perfection of extreme evil, an evil whose possibility spreads well beyond that which weapons of mass destruction bequeathed to the nation-states, on to a surprising and terrible empowerment.

Perfection of extreme evil now thats a mouthful.

Even Elon Musk, of Tesla Car and SpaceX Rocket Fame, is allegedly wary of A.I. According to CNN, he told an audience at MIT that we should be very careful about Artificial Intelligence, warning it may be our biggest existential threat, adding that with Artificial Intelligence, we are summoning the demon.

When so-called High Profile Illuminati Gofer Scientist-Entrepreneurs refer to Artificial Intelligence as Perfection of Extreme Evil and Summoning the Demons b******! You Better Pay Attention!

CONTINUE READING

URI DOWBENKO is the author of Homegrown Holography, Bushwhacked: Inside Stories of True Conspiracy and Hoodwinked: Watching Movies with Eyes Wide Open. He is also the founder and publisher of http://www.ConspiracyPlanet.com, http://www.ConspiracyDigest.com, http://www.AlMartinRaw.com, and http://www.InsiderIntelligence.com, as well as the publisher of The Conspirators: Secrets of an Iran Contra Insider by Al Martin. Uris latest project is called New Improved Memoirs, Its your life story Without the hassle of writing it. (http://www.NewImprovedMemoirs.com) a professional service for people who want to leave behind a customized autobiography, in other words a published book, as a legacy for their friends, family, and posterity. You can visit Uri at http://www.UriDowb

~~ Help Waking Times to raise the vibration by sharing this article with friends and family

Transhumanism: The Anti-Human Singularity Agenda was last modified: June 18th, 2016 by WakingTimes

15 Free Transformational Books for Waking Times Subscribers

Originally posted here:
Transhumanism: The Anti-Human Singularity Agenda

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

4 Easy Ways to Live a Healthy Lifestyle (with Pictures)

Edit Article

Four Parts:Choosing Healthy FoodsGetting Some ExerciseAvoiding Unhealthy HabitsRemembering Good HygieneCommunity Q&A

Being healthy involves more than eating an occasional salad or going for a short walk once every few weeks, but while you’ll need to put in some effort, your health is well worth it. To live a healthy lifestyle, consistently choose healthy foods, fit more exercise and physical activity into your daily routine, and practice good hygiene. You’ll also need to avoid unhealthy habits, like fad dieting and neglecting sleep. Making lifestyle improvements may require some gradual adjustment, but improved health is readily accessible once you commit to it. [1]

Part 1

1

2

3

4

5

Part 2

1

2

3

Exercise in your neighborhood. Go for a jog or take your dog for a walk. Make sure that you move at a moderate pace for at least 30 minutes.

4

5

Part 3

1

2

3

4

5

6

7

Part 4

1

2

3

Clean your feet. Make sure to scrub between your toes to prevent athlete’s foot and unpleasant odors.

4

5

How can I stop myself from eating so much?

wikiHow Contributor

Eat a high calorie breakfast! This will decrease your hunger for the rest of the day as well as speed up your metabolism. Make sure you drink a lot of water, and drink a glass before eating, since you will become full faster. Using smaller plates has a psychological effect which decreases the amount of food you eat. Also, try to limit the amount of sugar and empty calories you take in and eat more lean protein which will keep you full longer and less hungry.

How many hours should teenagers sleep?

wikiHow Contributor

Teenagers should get between eight and ten hours of sleep each night to be healthy.

What foods that I can eat for a few days to cleanse my body?

wikiHow Contributor

Lemon, cucumber, and basically any kind of veggie.

Should I stop eating sourdough bread? Is it considered a white bread, and is it unhealthy?

wikiHow Contributor

You don’t need to stop eating anything completely if you really like it; everything is okay in small doses. Sourdough isn’t generally considered white bread; it’s considered its own kind of bread, and some think it’s healthier than plain white bread. Whole wheat bread is healthier, though.

What is a good atmosphere for a healthy lifestyle?

wikiHow Contributor

A good atmosphere for a healthy lifestyle includes being around other people that have the same drive to be healthy, not around those that encourage unhealthy behaviors. Also, maintaining a clean house (especially kitchen) will make you feel like you’re more in control of your life and thus will help you lead a better life. Last but not least, remember that health is not a destination but a journey, so you must always be working towards a healthier body and life.

Is there an easy way to sleep well?

wikiHow Contributor

Yes. Just allot yourself enough time to get a good night’s sleep. Stick to a regular sleep schedule as best as you can, rather than sleeping and waking up at different times from day to day. Do not exercise within 2 hours of sleeping. Do not eat large amounts of food before going to sleep. Avoid caffeine or sugary foods and drinks before sleeping. Try not to use your TV, computer, phone, tablet or any other screen shortly before sleeping. Dim your lights before you go to sleep. All of this, combined with living a healthier lifestyle all around should greatly increase your quality of sleep.

How can I lose fat in the thigh and tummy area?

How much sleep should I get if I am 12 years old?

wikiHow Contributor

12-year-olds need about 9-10 hours of sleep every night to be healthy.

What happens if I only get 4 hours of sleep a night?

wikiHow Contributor

Once in a while it really won’t hurt you, but if it happens all the time your immune system will be affected, and you’ll be more likely to get sick. You’ll also be prone to fatigue, headaches, trouble concentrating, and other impairments.

Is jogging a way to lose drastic weight?

wikiHow Contributor

Yes, if you do it regularly and eat as few carbs as possible.

Ask a Question

Categories: Diet & Lifestyle

In other languages:

Italiano:Avere uno Stile di Vita Sano,Espaol:vivir un estilo de vida saludable,Deutsch:Einen gesunden Lebensstil pflegen,Portugus:Viver um Estilo de Vida Saudvel,: ,Franais:adopter un mode de vie sain,: ,Bahasa Indonesia:Menjalani Gaya Hidup Sehat,Nederlands:Een gezond leven leiden,:,Ting Vit:Sng mt li sng lnh mnh,:

Thanks to all authors for creating a page that has been read 1,052,340 times.

YesNo

Follow this link:
4 Easy Ways to Live a Healthy Lifestyle (with Pictures)

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

HCG PROTOCOL hCG Diet Injections Prescribed by Doctor

in just 3 weeks

*Individual results vary, but typical weight loss is between 2-3kgs per week

^HCGPROTOCOL provide pharmaceutical grade hCG by prescription from our doctor.

(available by either hCG injections or hCG sub-lingual spray)

We are located in Melbourne with 3 clinic locations: Port Melbourne, Oakleigh & St Kilda Road and offer our program to patients Australia wide with consultations viaSkype.

Contact Us Today to see if this program is right for you or simply complete our on-line Evaluation Formand we will contact you to schedule a consultation.

What is hCG? hCG (human Chorionic Gonadotrophin) is a biologically natural hormone that is produced in abundance in women during pregnancy, at which time its purpose is to use stored fat to nourish the developing fetuswhilst preserving the mothers muscle tone. When used in weight loss, hCG allows the body to mimic these effects on the bodyallowing you to readily access your fat stores. What many of us find so frustrating about stubborn fat deposits is that no amount of dieting or exercise seems to have an impact. The body seems to hold on to the fat no matter what you do. But they are accessible with hCG! It is also just as effective in males as it is in female; infact men tend to lose more weight, more quickly!

The hCG diet was originally developed by Dr. A.T.W. Simeonsa British endocrinologist who established a clinic in Italy in the 1950s, specialising in the treatment of clinically obese patients. Dr Simeons spent 40 years of his life in research and clinical observation of thousands of cases, leading to the concept of the hCG diet, which he documented in his manuscript Pounds and Inches.

In this manuscript Dr Simeons outlines his clinical observationsamongst them the discovery that hCG is effective in the treatment of fat loss when combined with a VLCD (very low calorie diet) as the body gets all of the nutrition it needs from stored fat reserves. Acting in this way, whilst undergoing an hCG diet weight loss cycle your appetite reduces, with no experience of hunger; such as would be certain without its effect in your system. It was further observed that hCG seemed to work to reset the hypothalamus. The hypothalamus is a master gland that regulates most of your bodys hormones, including metabolism and fat storage. The active hCG diet protocol cycle gets the weight to drop off quickly (average fatloss is 7kg in 3 weeksbut some lose even more); then with the hypothalamus set on the right trackand with guidance for some simple lifestyle strategies we can assist you tokeep the weight off permanently!!!

Click here to see Before and After Success Stories

No more worrying about exercising those abs or thighs like crazy, in hope of some miracle spot reductionhCG looks after this for you, resulting in more even fat distribution and more desirable overall shape.

For those who need to lose up to 7kg a 3 week hCG diet program is recommendedor those with more than 7kg to lose can opt to undergo a 6 week course. Alternatively, you may chose to undertake 2 separate 3 week programs, to give you a break in-between.

Visit us and Like us on Facebook to receive regular updates of special offers, hints and tips to improve your weight loss results or to ask any us questions you may have about the program.

Want a quick summary? Download HCG Diet ProtocolPDF: HCG Protocol_ Weight loss Brochure

Read the original:
HCG PROTOCOL hCG Diet Injections Prescribed by Doctor

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...

Testosterone Replacement Therapy Seattle WA – Dr Kate Kass

If youre like most men, you ignore health issues large and small, toughing it out until your body feels out of whack or accepting a slow decline in mood, motivation, and libido that you just chalk up to normal aging.

Perhaps you visit a primary care physician once a year who says everythings fine, but you have a growing belly, no energy, and your erectile function isnt what it used to be. Maybe you have an expanding medicine cabinet of pharmaceuticals that are causing unwanted side effects. Sound familiar?

Thats a shame because you dont have to live with subpar health. There are many ways to optimize your health at any age and restore the youthful energy and vigor you used to depend on. It could be your thyroid, leaky gut, side effects to medications, or elevated cortisol levels that are laying you low.

And it could be low testosterone. Low testosterone affects your sexual function, but it can also be the root cause of fatigue, weight gain, sleep apnea, and a whole laundry list of less-than-desirable symptoms. But the good news is, if you seek out the right help, you can prevent disease and regain a sense of wellness and vitality.

Thats where Dr. Kate Kass comes in. A licensed primary care physician, Dr. Kass specializes in functional medicine, age management, and mens sexual wellness.

She seeks out cutting-edge therapies, tests, and protocols from the worlds of conventional and functional medicine to diagnose the root problem and create an effective treatment plan customized to your specific symptoms and concerns. (Read more about Dr. Kasss philosophy)

Starting around a mans mid-30s, total testosterone declines at a rate of 10 percent each decade and more than 40 percent of males 40 and above have a testosterone deficiency.

It is during this time that men experience andropause, the male counterpart to menopause. Testosterone is tricky. It doesnt just affect sexual performance. In fact, you actually may have satisfactory erectile function but still test below optimal levels for testosterone.

Why does this matter? Because testosterone is a factor in all sorts of bodily functions. When your levels are optimal, testosterone protects against cardiovascular disease, reduces blood sugar, improves lean muscle mass, increases bone density, decreases cholesterol, and increases libido and sexual performance.

Its a powerful tool in preventing disease and improving your quality of life. When you have low testosterone, however, you may experience the following symptoms:

If any of these symptoms strike a chord, you may have a testosterone decline, and you should seek out an expert for a comprehensive evaluation.

As a specialist in testosterone replacement therapy in Seattle, Dr. Kass believes that you dont have to resign yourself to unwanted symptoms of aging.

In her practice, she has helped male patients regain vitality and their libido, manage their weight, and improve their mood – all while slowing the aging process and preventing disease.

Dr. Kass has extensive training and experience in all the safe, effective methods of testosterone delivery, and is one of the few practitioners trained to offer testosterone via pellet implantation.

Dr. Kass fine tunes your treatment, and manages the various adjunctive hormones that also play a role in optimizing testosterone function and your overall health.

Read more here:
Testosterone Replacement Therapy Seattle WA – Dr Kate Kass

Recommendation and review posted by Alexandra Lee Anderson

Read the Rest...